

## Author's reply

Sir,

I thank the authors for welcoming the criticism on 19<sup>th</sup> Model List of Essential Medicines (EML) in their correspondence. One needs to remember that the majority of the global population dwells in developing countries and in places inaccessible to sophisticated tertiary care. The hands of the health care worker serving in the primary health centers and communities of these areas are unclean and loaded with variable amounts of organic material. The guidelines including the World Health Organization (WHO) state that in this context, handwashing with soap and water is superior to alcohol-based hand rub.<sup>[1]</sup> We also need to remember that “cost-effectiveness” is considered rather than efficacy while selecting a drug for essential medicines list. So, in the other context also, handwashing with soap and water should be preferred over alcohol-based hand rub for inclusion in the WHO EML.

The reference (no. 3) quoted by the authors of the correspondence with regards to their argument on daclatasvir is a news release issued by the United States Food and Drug Administration (US FDA) on 24 July 2015 which states that “Today’s approval provides a new option ....” The drug was approved in July 2015, but the 19<sup>th</sup> EML was released on April 2015. So, WHO has included an investigational agent in their list.

The approval of bedaquiline was based on phase 2 trials.<sup>[2]</sup> Bedaquiline got approval under accelerated approval program<sup>[2]</sup> and the authors of the letter themselves write that the European Medicines Agency has given a conditional marketing authorization. So, it is very clear that it has not been completely registered.

It would be very much appreciated if the readers get the broader picture of the issues highlighted in the editorial. These issues should be considered by every country while developing the national list based on the model list.

**Manikandan S**

*Associate Editor, JPP, Department of Pharmacology,  
Jawaharlal Institute of Postgraduate Medical Education and  
Research, Pondicherry, India*

**Address for correspondence:**

Manikandan S, Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India.  
E-mail: drsmanikandan001@gmail.com

**Received:** 28-09-2015

**Accepted:** 29-10-2015

## REFERENCES

1. Who.int. Geneva: World Health Organization. Available from: [http://www.who.int/gpsc/tools/faqs/system\\_change/en/](http://www.who.int/gpsc/tools/faqs/system_change/en/). [Last accessed on 2015 Sep 27].
2. fda.gov. Maryland: Food and Drug Administration. Available from: <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333695.htm>. [Last accessed on 2015 Sep 27].

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Access this article online	
Quick Response Code:	<b>Website:</b> <a href="http://www.jpharmacol.com">www.jpharmacol.com</a>
	

**How to cite this article:** Manikandan S. Author's reply. J Pharmacol Pharmacother 2015;6:235.